{'52WeekChange': -0.058202267,
 'SandP52WeekChange': 0.0644362,
 'address1': '110 East 59th Street',
 'address2': 'Floor 33',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 41.78,
 'askSize': 1000,
 'averageDailyVolume10Day': 1283900,
 'averageVolume': 3296889,
 'averageVolume10days': 1283900,
 'beta': None,
 'beta3Year': None,
 'bid': 41.1,
 'bidSize': 800,
 'bookValue': None,
 'category': None,
 'circulatingSupply': None,
 'city': 'New York',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 42.4,
 'dayLow': 39.9,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': -0.806,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': None,
 'enterpriseValue': None,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 46.701427,
 'fiftyTwoWeekHigh': 56.5,
 'fiftyTwoWeekLow': 39.9,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': None,
 'forwardEps': None,
 'forwardPE': None,
 'fromCurrency': None,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': None,
 'heldPercentInstitutions': None,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/royaltypharma.com',
 'longBusinessSummary': 'Royalty Pharma plc operates in the biopharmaceutical '
                        'industry. The company operates as a buyer of '
                        'biopharmaceutical royalties and a funder of '
                        'innovation in the biopharmaceutical industry. It is '
                        'involved in the identification, evaluation, and '
                        'acquisition of royalties and royalty-related assets '
                        'on various biopharmaceutical therapies. The company '
                        'collaborates with innovators from academic '
                        'institutions, research hospitals, small and mid-cap '
                        'biotechnology companies, and pharmaceutical '
                        'companies. Its portfolio includes royalties on '
                        'approximately 45 commercial products and three '
                        'development-stage product candidates. It has '
                        'royalties on various therapeutic areas and drug '
                        'classes, including Neulasta, Neupogen, Rituxan, '
                        'Imbruvica, Trodelvy, Tazverik, and Xtandi in '
                        'oncology; Lyrica in neuropathic pain; Biktarvy, '
                        'Genvoya, Prezista, Symtuza, Truvada, and Atripla in '
                        'HIV; Humira, Remicade, and Cimzia TNF inhibitors; '
                        'Kalydeco, Orkambi, Symdeko, and Trikafta in cystic '
                        'fibrosis; Tecfidera and Tysabri in multiple '
                        'sclerosis; Emgality, Nurtec ODT (rimegepant), and '
                        'vazegepant in migraine; and others. The company was '
                        'founded in 1996 and is based in New York, New York.',
 'longName': 'Royalty Pharma plc',
 'market': 'us_market',
 'marketCap': 25440837632,
 'maxAge': 1,
 'maxSupply': None,
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': 2052331008,
 'nextFiscalYearEnd': 1640908800,
 'open': 42.32,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '212 883 0200',
 'previousClose': 42.89,
 'priceHint': 2,
 'priceToBook': None,
 'priceToSalesTrailing12Months': 13.530561,
 'profitMargins': 1.09152,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 42.4,
 'regularMarketDayLow': 39.9,
 'regularMarketOpen': 42.32,
 'regularMarketPreviousClose': 42.89,
 'regularMarketPrice': 42.32,
 'regularMarketVolume': 1749942,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 365828000,
 'sharesPercentSharesOut': 0.0033000002,
 'sharesShort': 2014531,
 'sharesShortPreviousMonthDate': None,
 'sharesShortPriorMonth': None,
 'shortName': 'Royalty Pharma plc',
 'shortPercentOfFloat': 0.0076,
 'shortRatio': 0.32,
 'startDate': None,
 'state': 'NY',
 'strikePrice': None,
 'symbol': 'RPRX',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': None,
 'twoHundredDayAverage': 46.701427,
 'volume': 1749942,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.royaltypharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '10022'}